Metronidazole Milpharm

Metronidazole, the active ingredient in Metronidazole Milpharm, is a nitroimidazole antibiotic presented as an oral dosage form for oral use. It treats bacterial vaginosis, trichomoniasis, amoebiasis and anaerobic infections in adult patients.

GNH USA supplies Metronidazole Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to healthcare providers across multiple continents. Our global network ensures reliable delivery, competitive pricing, and comprehensive support for product registration and post‑market surveillance.

Metronidazole is used to treat infections caused by susceptible anaerobic bacteria and certain protozoa.

- Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic bacteria. - Trichomoniasis: eradicates Trichomonas vaginalis infection, relieving symptoms. - Amoebiasis: treats intestinal Entamoeba histolytica infection, preventing dysentery. - Anaerobic infections: combats mixed anaerobic infections in intra‑abdominal, pelvic and soft‑tissue sites.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach or feeling sick. - Metallic taste: a transient metallic sensation in the mouth. - Headache: mild to moderate head pain. - Abdominal pain: cramping or discomfort in the stomach area. - Diarrhea: loose stools occurring during therapy. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: convulsions requiring immediate medical attention. - Peripheral neuropathy: tingling, numbness, or burning sensations in extremities. - Severe allergic reactions: rash, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatotoxicity: liver enzyme elevations or hepatitis. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Pseudomembranous colitis: severe colonic inflammation caused by Clostridioides difficile.

Before initiating therapy, consider the following safety measures.

- Assess renal and hepatic function: adjust therapy in patients with impairment. - Avoid alcohol: concurrent intake may cause a disulfiram‑like reaction. - Monitor for neurological symptoms: report numbness or tingling promptly. - Use with caution in pregnancy: only if benefits outweigh risks. - Inform patients about possible metallic taste and gastrointestinal upset. - Store at below 25°C: keep in the original container, protect from moisture and light.

Metronidazole can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Alcohol: may cause severe nausea, vomiting, flushing, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing INR and bleeding risk. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenobarbital: may reduce metronidazole levels, decreasing efficacy. - Oral contraceptives: may reduce hormonal effectiveness; advise backup contraception.